TY - JOUR
T1 - The effect of chlorzoxazone on acute pain after spine surgery. A randomized, blinded trial
AU - Nielsen, R. V.
AU - Fomsgaard, J. S.
AU - Siegel, H.
AU - Martusevicius, R.
AU - Mathiesen, O.
AU - Dahl, J. B.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background: Chlorzoxazone is a muscle relaxant administered for musculoskeletal pain, and as an analgesic adjunct for post-operative pain. Chlorzoxazone for low back pain is currently not advised due to the lack of placebo-controlled trials. We explored the effect of chlorzoxazone on acute pain after spine surgery. Methods: One hundred and ten patients were randomly assigned to 500 mg oral chlorzoxazone or placebo in this blinded study of patients having spine surgery under general anaesthesia. In the 4 h trial period analgesia consisted of IV patient-controlled analgesia (morphine bolus 2.5 mg). Primary outcome was pain during mobilization (visual analogue scale) 2 h after the intervention. Secondary outcomes were pain at rest, opioid consumption, nausea, vomiting, sedation and dizziness. Results: For pain during mobilization 2 h after intervention, there was no significant difference between groups: 51 (21) vs. 54 (25) mm in the chlorzoxazone and placebo groups, respectively, mean difference 3 mm (95% CI −8 to 10), P = 0.59. For pain during mobilization and at rest (wAUC 1–4 h), there were no significant differences between groups. There was no significant difference in total IV morphine use 0–4 h: median 10 (7–21) vs. 13 (5–19) mg in the chlorzoxazone and placebo groups, respectively, P = 0.82. We found no significant difference in adverse effects. Conclusion: No analgesic effect of single-dose chlorzoxazone was demonstrated in patients with acute pain after spine surgery. Based on these findings, chlorzoxazone cannot be recommended for immediate treatment of acute pain after such procedures.
AB - Background: Chlorzoxazone is a muscle relaxant administered for musculoskeletal pain, and as an analgesic adjunct for post-operative pain. Chlorzoxazone for low back pain is currently not advised due to the lack of placebo-controlled trials. We explored the effect of chlorzoxazone on acute pain after spine surgery. Methods: One hundred and ten patients were randomly assigned to 500 mg oral chlorzoxazone or placebo in this blinded study of patients having spine surgery under general anaesthesia. In the 4 h trial period analgesia consisted of IV patient-controlled analgesia (morphine bolus 2.5 mg). Primary outcome was pain during mobilization (visual analogue scale) 2 h after the intervention. Secondary outcomes were pain at rest, opioid consumption, nausea, vomiting, sedation and dizziness. Results: For pain during mobilization 2 h after intervention, there was no significant difference between groups: 51 (21) vs. 54 (25) mm in the chlorzoxazone and placebo groups, respectively, mean difference 3 mm (95% CI −8 to 10), P = 0.59. For pain during mobilization and at rest (wAUC 1–4 h), there were no significant differences between groups. There was no significant difference in total IV morphine use 0–4 h: median 10 (7–21) vs. 13 (5–19) mg in the chlorzoxazone and placebo groups, respectively, P = 0.82. We found no significant difference in adverse effects. Conclusion: No analgesic effect of single-dose chlorzoxazone was demonstrated in patients with acute pain after spine surgery. Based on these findings, chlorzoxazone cannot be recommended for immediate treatment of acute pain after such procedures.
UR - http://www.scopus.com/inward/record.url?scp=84982855929&partnerID=8YFLogxK
U2 - 10.1111/aas.12754
DO - 10.1111/aas.12754
M3 - Article
C2 - 27306492
AN - SCOPUS:84982855929
VL - 60
SP - 1152
EP - 1160
JO - Acta Anaesthesiologica Scandinavica
JF - Acta Anaesthesiologica Scandinavica
SN - 0001-5172
IS - 8
ER -